This article is more than 5 years old. Information may no longer be current.
Inveltys now available in US
Kala Pharmaceuticals has launched its twice-daily ocular corticosteroid Inveltys in the United States, according to a press release.
Inveltys (loteprednol etabonate ophthalmic suspension 1%), which uses Kala’s Ampplify mucus-penetrating particle drug delivery technology to enhance penetration into target tissues, is indicated for the treatment of postoperative inflammation and pain after ocular surgery.
The company has hired a specialty sales force of 57 territory sales managers, the release said.
“Formulary contract bids are in discussion for commercial insurance coverage in 2019 and Medicare Part D program coverage beginning in 2020. Furthermore, through the availability of a co-pay assistance program, all patients will have immediate access to Inveltys at launch,” Todd Bazemore, Kala chief operating officer, said in the release.